Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2025-02-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daewoong Co., Ltd. It contains the meeting agenda, date, location, voting procedures (including electronic voting), and detailed management reference materials (business overview, financial statements, and board activities). This document is a formal proxy statement and meeting notice sent to shareholders to solicit votes for the upcoming Annual General Meeting. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement.
2025-02-25 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy Reference Document) and is filed by Daewoong Co., Ltd. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and proxy solicitation details. While it includes financial statements as reference material for the meeting, the primary purpose of the document is to solicit proxies for the AGM, which falls under the Proxy Solicitation & Information Statement category.
2025-02-25 Korean
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) for their subsidiary Daewoong Pharmaceutical. It details a supply agreement for Botulinum Toxin (Nabota) in Brazil, including contract value, duration, and counterparty information. This type of disclosure regarding material business contracts is classified as a general regulatory filing (RNS) as it does not fit into specific categories like M&A, dividends, or financial reports.
2025-02-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from Daewoong regarding a significant change in sales or profit structure (30% or more). This is a standard financial disclosure required by the Korea Exchange (KRX) when a company's financial performance deviates significantly from the previous period. It provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the variance. It is not a full annual report (10-K) or an earnings release (ER) in the traditional sense, but rather a specific regulatory disclosure of financial results. Given the nature of the filing as a mandatory regulatory disclosure of financial performance, 'RNS' (Regulatory Filings) is the most appropriate classification.
2025-02-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)
Management Reports Classification · 95% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a change in financial structure (revenue/profit) of 30% or more. It provides preliminary financial data (revenue, operating profit, net income) for the fiscal year compared to the previous year. This is a standard regulatory disclosure for listed companies in Korea to report significant financial changes before the final audit report is filed. It fits the 'Earnings Release' (ER) category as it provides the initial announcement of financial results highlights.
2025-02-10 Korean
단일판매ㆍ공급계약해지(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding the termination of a supply contract by Daewoong Pharmaceutical. It details the contract cancellation, the reason (breach of contract by the counterparty), and the financial impact. Since this is a specific regulatory disclosure of a material event (contract termination) that does not fit into categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2024-12-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.